The Translational Immunogenomics Laboratory (TIGL) was established to assist investigators at Dana-Farber Cancer Institute (DFCI) and its partners in advancing cancer immunotherapy research through state-of-the-art systems for molecular and cellular analysis of immune response to cancer therapeutics.
TIGL evaluates the latest developments in the field, implements the optimal protocol, and invents methods when current approaches are inadequate. We use genomics (often at the single-cell level), proteomics, molecular immunology, and computational methods to study antigen-specific interactions and their involvement in pathways underling anti-tumor immunity.
Our experienced personnel are committed to discovering and exploring essential and translational approaches in immune-oncology, and we offer technical support and scientific advice to investigators at DFCI and its partners who are interested in studying the immune response to cancer therapeutics.